Amended Statement of Changes in Beneficial Ownership (4/a)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Schor Chen	2. Issuer Name and Ticker or Trading Symbol Adicet Bio, Inc. [ ACET ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) President and CEO
(Last) (First) (Middle) C/O ADICET BIO, INC., 500 BOYLSTON STREET, 13TH FLOOR	3. Date of Earliest Transaction (MM/DD/YYYY) 3/16/2021
(Street) BOSTON, MA 02116 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY) 3/18/2021	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	3/16/2021		S⁽¹⁾		6474	D	$15.07 ⁽²⁾	155218	I	See footnote ⁽⁴⁾
Common Stock	3/16/2021		S⁽¹⁾		5395	D	$15.66 ⁽³⁾	129318	I	See footnote ⁽⁵⁾
Common Stock	3/16/2021		S⁽¹⁾		2508	D	$15.07 ⁽²⁾	152710	I	See footnote ⁽⁴⁾
Common Stock	3/16/2021		S⁽¹⁾		2089	D	$15.66 ⁽³⁾	127229	I	See footnote ⁽⁵⁾
Common Stock	1/22/2021		G	V	26070 ⁽⁶⁾	D	⁽⁶⁾	0	D ⁽⁶⁾
Common Stock	1/22/2021		G	V	22985 ⁽⁷⁾	D	⁽⁷⁾	0	I	See footnote ⁽⁷⁾
Common Stock	1/22/2021		G	V	23570 ⁽⁸⁾	D	⁽⁸⁾	0	I	See footnote ⁽⁸⁾
Common Stock	1/25/2021		G	V	19286 ⁽⁹⁾	D	⁽⁹⁾	0	I	See footnote ⁽⁹⁾
Common Stock	1/25/2021		G	V	27014 ⁽¹⁰⁾	D	⁽¹⁰⁾	0	I	See footnote ⁽¹⁰⁾

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:
(1)	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
(2)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $14.49 to $15.48, inclusive.
(3)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $15.50 to $16.02, inclusive.
(4)	Represents 152,710 shares held directly by an irrevocable family trust having an independent trustee.
(5)	Represents 127,229 shares held directly by an irrevocable family trust having an independent trustee.
(6)	Represents 26,070 shares transferred by gift by the Reporting Person to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4.
(7)	Represents 22,985 shares transferred by gift by a revocable family trust of which the Reporting Person is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4.
(8)	Represents 23,570 shares transferred by gift by a revocable family trust of which the Reporting Person is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4.
(9)	Represents 19,286 shares transferred by gift by a grantor retained annuity trust of which the Reporting Person's spouse is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4.
(10)	Represents 27,014 shares transferred by gift by a grantor retained annuity trust of which the Reporting Person is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Schor Chen C/O ADICET BIO, INC. 500 BOYLSTON STREET, 13TH FLOOR BOSTON, MA 02116	X		President and CEO